|Videos|March 15, 2022
Decentralized Clinical Trials in a Covid-19 Landscape
Author(s)YPrime
YPrime President, Mark Maietta, discusses the future of decentralized clinical trials following Covid-19. Adaptations will need to be made as DCT is here to stay.
• Regulatory has begun to investigate new methods and technologies for the clinical trial process.
• Clinical trials will have more decentralized components going forward.
• The key is matching a protocol and patient with the new components of DCT.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results
2
ACT Brief: Building a Digital Thread in Life Sciences, CRO Sourcing Decisions and Site Burden, and Lilly’s Oral GLP-1 Phase III Results
3
Controlled Clinical Trials in Sub-Saharan Africa: A Winning Value Proposition
4
FDA Approves Subcutaneous Lunsumio VELO Based on GO29781 Trial Results in Relapsed or Refractory Follicular Lymphoma
5